Humanin Research: Mitochondria-Derived Peptide and Neuroprotection

Humanin is a 21 amino acid peptide encoded within the mitochondrial 16S ribosomal RNA gene (MT-RNR2) in an alternative open reading frame. Its discovery by Hashimoto et al. in 2001 (PNAS) through expression cloning screening for factors protecting neuronal cells from mutant amyloid precursor protein toxicity established the first known mitochondria-encoded cytoprotective peptide and launched the field of mitochondria-derived peptides (MDPs).

Discovery and the MDP Field

The identification of Humanin from a cDNA library derived from occipital lobe of an Alzheimer disease patient — screening for clones that rescued cortical neurons from APP mutant-induced apoptosis — was unexpected because the protective sequence mapped to the mitochondrial genome rather than the nuclear genome. This discovery challenged the prevailing understanding that the mitochondrial genome encoded only 13 proteins (all components of the oxidative phosphorylation machinery), 22 tRNAs, and 2 rRNAs — with no signalling peptides.

Subsequent research established the MDP family: MOTS-c (encoded in the 12S rRNA gene), six small humanin-like peptides (SHLP1-6) encoded in the 16S rRNA locus alongside Humanin, and potentially additional MDPs still being characterised. These findings established that the mitochondrial genome functions as a source of bioactive signalling peptides — not merely a compact energy metabolism gene cluster — with profound implications for understanding mitochondrial retrograde signalling.

Receptor Systems

CNTFR/WSX-1/gp130 tripartite complex: Humanin activates the same heterotrimeric receptor complex used by ciliary neurotrophic factor (CNTF) and cardiotrophin-1. This complex consists of CNTFR (ligand binding alpha subunit), WSX-1 (IL-27 receptor alpha, signal-transducing subunit), and gp130 (IL-6 receptor signal transducer, shared across the IL-6 family). Receptor activation drives JAK1/JAK2 phosphorylation, followed by STAT3 phosphorylation at Tyr705 (the primary downstream readout for Humanin's receptor-mediated neuroprotective signalling).

IGFBP-3 interaction: Humanin also signals through IGFBP-3 (insulin-like growth factor binding protein 3) and its putative receptor, with published data suggesting a functional interaction between Humanin and the IGF axis. The physiological significance of this interaction relative to the CNTFR complex pathway remains an active research question.

G14 critical residue: Structure-activity relationship research has established that glycine at position 14 (G14) is essential for neuroprotective activity. The G14A substitution (Humanin[G14A]) abolishes neuroprotection while retaining receptor binding, making it a useful negative control tool. Request G14A-Humanin from Signal Labs if studying receptor binding independently of downstream neuroprotective function.

Neuroprotection Research

APP toxicity model: Cortical neurons from embryonic day 18 rat cortex, cultured until DIV14. Treat with conditioned medium from APP-V717F-expressing cells (which contains toxic APP-related fragments) with and without Humanin (1fM-10nM) co-treatment. Measure viability by calcein-AM/ethidium homodimer (live-dead) imaging at 24-48 hours. Include Humanin[G14A] at matched concentrations as negative control to confirm sequence-dependent neuroprotection.

Beta-amyloid toxicity: Prepare Abeta42 oligomers by dissolving peptide in HFIP, drying, reconstituting in DMSO at 5mM, then diluting in F12 medium and incubating at 4°C for 24 hours. Apply Abeta42 oligomers (5µM) to cortical neurons with or without Humanin pre-treatment (1 hour prior, 1nM-1µM). Assess: viability (MTT); caspase-3 activity (fluorogenic substrate); phospho-STAT3 (Western blot, 15 minutes Humanin pre-treatment before readout); and neurite integrity (MAP2 immunofluorescence, automated analysis of neurite length and branching).

Oxidative stress model: H2O2 (100-500µM, 4 hours) applied to SH-SY5Y cells or primary neurons. Humanin pre-treatment (1 hour) at 1pM-100nM. Endpoints: cell viability (trypan blue exclusion, LDH release), ROS measurement (CM-H2DCFDA fluorescence), mitochondrial membrane potential (JC-1), and Bcl-2/Bax ratio by Western blot.

Metabolic Research

Beyond neuroprotection, published research has connected Humanin to metabolic function. In hepatocytes, Humanin activates STAT3 signalling to suppress glucose output — a potential mechanism for hepatic insulin sensitisation. In adipocytes, Humanin has been proposed to modulate adiponectin secretion. Plasma Humanin concentrations decline with age in humans, paralleling the age-related increase in metabolic syndrome prevalence.

Hepatocyte glucose output assay: Primary rat hepatocytes or HepG2 cells stimulated with glucagon (100nM) to activate glycogenolysis and gluconeogenesis. Humanin treatment (1nM-1µM) before or alongside glucagon stimulation. Measure glucose in conditioned medium by glucose oxidase assay at 6 and 24 hours. Confirm STAT3 involvement using the gp130 inhibitor SC144 (10µM).

Key Published Research

• Hashimoto Y, et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ." PNAS, 2001. PMID: 11717412
• Guo B, et al. "Humanin peptide suppresses apoptosis by interfering with Bax activation." Nature, 2003. PMID: 14576432
• Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 2015. PMID: 25738459

View Humanin →

For laboratory and analytical research purposes only. Not for human or veterinary use.

Humanin and Age-Related Disease Research

Circulating Humanin concentrations decline with age in humans — measured by ELISA and LC-MS/MS in plasma samples from young adults versus elderly populations in published cross-sectional studies. This age-dependent decline in an endogenous mitochondria-derived neuroprotective peptide has stimulated research into whether Humanin decline contributes to age-related neurological vulnerability, and whether restoration of Humanin concentrations produces measurable protective effects in aged cell models.

For aged neuron models: primary cortical neurons from embryonic day 18 rats are compared with neurons from postnatal day 3 rats (which recapitulate a more differentiated but less proliferative state) or with neurons from adult brain neurosphere cultures. Alternatively, human induced pluripotent stem cell (iPSC)-derived neurons from aged donors (60+ years) versus young donors (20-30 years) show intrinsic ageing-associated transcriptional differences that provide a human cell model for testing Humanin's neuroprotective effects in the context of biological ageing.

Humanin Analogues and Structure-Activity Research

The critical G14 residue identified through alanine scanning mutagenesis makes position 14 the key pharmacophore anchor. Research with Humanin analogues — specifically the active S14G-Humanin (S14G substitution that increases potency approximately 1000-fold in some published assays) alongside standard Humanin — characterises potency-response relationships and informs the receptor interaction geometry.

S14G-Humanin (HNG) was published by Hashimoto's group as a hyperpotent Humanin analogue showing dramatically enhanced neuroprotection in APP-toxicity and beta-amyloid models. Running HNG alongside Humanin and G14A-Humanin (negative control) in the same assay establishes a complete pharmacological reference frame: HNG (maximum potency), Humanin (standard potency), G14A-Humanin (negligible activity). Any research compound producing neuroprotective effects in the range between G14A-Humanin and HNG responses can be accurately positioned within this pharmacological framework.

Humanin and Reproductive Biology

An unexpected dimension of Humanin biology identified in published research is its expression in the testis and ovary, with proposed roles in germ cell and reproductive cell survival. Humanin expression is high in Sertoli cells and Leydig cells; CNTFR/gp130 receptor complex components are expressed in spermatogonia. Published research has examined Humanin in male reproductive cell apoptosis models — protecting spermatogenic cells from chemotherapy-induced apoptosis through the same STAT3/Bcl-2 neuroprotective pathway characterised in neurons. This reproductive biology dimension suggests Humanin research relevance beyond the CNS, connecting it to gonadal function research.

Humanin Quantification Methods

Accurate measurement of Humanin concentrations in biological samples is essential for pharmacokinetic research and for correlating Humanin levels with biological outcomes. Multiple measurement approaches are available with different sensitivity and specificity profiles.

ELISA: Commercial Humanin ELISA kits are available from multiple suppliers. Sensitivity varies between kits (typically 10-50 pg/mL), and specificity must be confirmed by testing cross-reactivity with SHLP peptides (SHLP1-6) which share sequence homology with Humanin. Include heat-inactivated Humanin as a negative control to confirm antibody specificity for the folded or linear peptide conformation.

LC-MS/MS: Mass spectrometry provides the most specific Humanin quantification, particularly important for plasma samples where non-specific antibody binding can produce falsely elevated ELISA signals. Use stable isotope-labelled Humanin (13C/15N-labelled, commercially available) as an internal standard added before sample preparation. Plasma protein precipitation with acetonitrile (3:1 v/v), followed by C18 solid-phase extraction and reverse-phase HPLC-MS/MS, provides a validated bioanalytical method for Humanin quantification in biological matrices.

Age-matched sampling: Cross-sectional studies comparing plasma Humanin in young (20-30 year), middle-aged (40-55 year), and elderly (65+ year) donors require careful matching of confounding variables — sex, BMI, exercise status, medication use, and disease status all affect Humanin concentrations. Published cross-sectional data consistently shows age-dependent Humanin decline but with substantial inter-individual variability that requires large sample sizes for statistical confidence.

Humanin and Mitochondrial Function Research

As a mitochondria-derived peptide, Humanin's biology is fundamentally connected to mitochondrial function — both as a readout of mitochondrial stress (Humanin expression is induced by mitochondrial perturbation) and as a regulator of mitochondrial biology (Humanin has been proposed to protect mitochondrial membrane integrity and reduce mitochondrial ROS).

For mitochondrial function research alongside Humanin: Seahorse XF analysis measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in real time. Humanin treatment (1pM-10nM) of neuronal cells or cardiomyocytes before mitochondrial stress (oligomycin to measure ATP-linked respiration, FCCP to measure maximal respiratory capacity, rotenone/antimycin A to measure non-mitochondrial oxygen consumption) characterises whether Humanin modulates mitochondrial respiratory function. MitoSOX Red (mitochondrial superoxide indicator) measures mitochondrial ROS production — if Humanin reduces MitoSOX fluorescence in stressed cells, this supports a mitochondrial antioxidant mechanism for the cytoprotective effects.

Humanin's circulating levels have been measured in plasma from cohorts spanning multiple decades of age. Published data from Cohen et al. (Nature Medicine, 2023) and related studies show that plasma Humanin declines substantially between the third and eighth decade of life, with accelerated decline associated with metabolic disease and cognitive impairment. This positions plasma Humanin as a potential biomarker of biological ageing rate — an area of active research using LC-MS/MS quantification rather than ELISA, given the need for high specificity to distinguish Humanin from related SHLP family members at low plasma concentrations. For research requiring internal standard-validated quantification, stable isotope-labelled Humanin (13C/15N uniformly labelled) provides the ideal internal standard for pharmacokinetic and biomarker studies.